11月21日，瑞迈特涨5.18%，截至发稿，报97.00元/股，成交1.27亿元，换手率1.92%，总市值86.91亿 元。瑞迈特股价已经连续5天上涨，区间累计涨幅11.11%。 资料显示，北京瑞迈特医疗科技股份有限公司位于北京市丰台区丽泽路16号院4号楼北京汇亚大厦17层 10号，成立日期2001年7月27日，上市日期2022年11月1日，公司主营业务涉及研发、生产、销售呼吸健 康领域医疗设备与耗材产品及相关服务,为以阻塞型睡眠呼吸暂停低通气综合征(OSA)为主的睡眠呼吸暂 停低通气综合征(SAHS)患者以及以慢性阻塞性肺疾病(COPD)为主的呼吸功能不全(Respiratory Insufficiency)患者提供全周期(从诊断、治疗到慢病管理)、多场景(从医疗机构到家庭)的治疗服务整体解 决方案。主营业务收入构成为：家用呼吸诊疗产品64.19%，耗材32.67%，医用产品3.05%，其他 0.10%。 信澳中小盘混合A（610004）基金经理为曾国富、李点典。 截至发稿，曾国富累计任职时间17年119天，现任基金资产总规模5.85亿元，任职期间最佳基金回报 109.1%， 任职期间最差基金回报-57.4 ...

金信价值精选混合A（005117）成立日期2017年9月1日，最新规模1340.48万。今年以来收益54.11%，同 类排名664/8140；近一年收益52.12%，同类排名684/8057；成立以来收益72.93%。 金信价值精选混合A（005117）基金经理为刘尚、谭智汨。 截至发稿，刘尚累计任职时间88天，现任基金资产总规模1.09亿元，任职期间最佳基金回报-7.12%， 任 职期间最差基金回报-12.32%。 谭智汨累计任职时间223天，现任基金资产总规模1.41亿元，任职期间最佳基金回报31.61%， 任职期间 最差基金回报-1.05%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 11月18日，瑞迈特涨5.01%，截至发稿，报88.86元/股，成交7130.86万元，换手率1.16%，总市值79.62 亿元。 资料显示，北京瑞迈特医疗科技股份有限公司位于北京市丰台区丽泽路16号院4号楼北京汇亚大厦17层 10号，成立日期2001年7月27日，上市日期202 ...

Core Viewpoint - The company 瑞迈特 has experienced fluctuations in its stock price and trading volume, with a notable increase in revenue and net profit year-on-year, indicating strong business performance despite recent market movements [1][3]. Group 1: Stock Performance - As of November 4, 瑞迈特's stock price decreased by 2.03% to 86.07 CNY per share, with a trading volume of 74.94 million CNY and a turnover rate of 1.22%, resulting in a total market capitalization of 7.71 billion CNY [1]. - Year-to-date, 瑞迈特's stock price has increased by 37.49%, with a 4.23% rise over the last five trading days and a 3.82% increase over the last 20 days, while it has seen a decline of 1.65% over the past 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, 瑞迈特 reported a revenue of 808 million CNY, representing a year-on-year growth of 34.24%, and a net profit attributable to shareholders of 180 million CNY, which is a 43.87% increase compared to the previous year [3]. - The company has distributed a total of 228 million CNY in dividends since its A-share listing [4]. Group 3: Business Overview - 瑞迈特, established on July 27, 2001, and listed on November 1, 2022, specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2]. - The revenue composition of 瑞迈特 includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is associated with concepts such as medical devices, small-cap stocks, and financing [2].

Group 1 - The core point of the article is that Ruimait (SZ 301367) held its 16th meeting of the third board session on October 27, 2025, to review the full report for the third quarter of 2025 [1] - For the first half of 2025, Ruimait's revenue composition was as follows: home ventilators accounted for 64.19%, consumables 32.67%, medical products 3.05%, and other businesses 0.1% [1] - As of the time of reporting, Ruimait's market capitalization was 7.6 billion yuan [1] Group 2 - The article also mentions a significant development regarding the private shipping king taking over Shanshan Group, indicating potential complexities in the restructuring process [1]

Group 1 - The core viewpoint of the news is that Ruimait Medical Technology Co., Ltd. has seen a stock price increase of 5.09%, reaching 89.20 yuan per share, with a total market capitalization of 7.992 billion yuan [1] - Ruimait specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea-hypopnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The company's main business revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Group 2 - According to data, Nord Fund's Nord Small and Mid-Cap Mixed Fund holds 18,000 shares of Ruimait, accounting for 5.02% of the fund's net value, making it the fifth-largest holding [2] - The Nord Small and Mid-Cap Mixed Fund has achieved a year-to-date return of 35.43%, ranking 1958 out of 8154 in its category [2] - The fund manager, Zhu Mingrui, has been in position for 3 years and 114 days, with the best fund return during his tenure being 25.82% [3]

Group 1 - The core viewpoint of the news is that Ruimait's stock price has experienced fluctuations, with a recent decline of 2.06% and a year-to-date increase of 36.38% [1][2] - As of October 23, Ruimait's stock price is reported at 85.38 CNY per share, with a market capitalization of 7.65 billion CNY [1] - The company has seen a net outflow of 485,500 CNY in principal funds, with large orders accounting for 18.86% of purchases and 21.33% of sales [1] Group 2 - Ruimait's main business involves the research, production, and sales of medical devices and consumables in the respiratory health field, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2] - The revenue composition of Ruimait includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2] - As of June 30, the number of shareholders decreased by 24.87% to 6,850, while the average circulating shares per person increased by 33.11% to 8,251 shares [3] Group 3 - For the first half of 2025, Ruimait achieved operating revenue of 544 million CNY, representing a year-on-year growth of 42.30%, and a net profit attributable to shareholders of 131 million CNY, also up by 42.19% [3] - Since its A-share listing, Ruimait has distributed a total of 228 million CNY in dividends [4] - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [4]

Core Viewpoint - 瑞迈特医疗科技股份有限公司 has shown a significant increase in stock price, indicating positive market sentiment and potential growth in the respiratory health sector [1] Company Overview - 瑞迈特医疗科技股份有限公司, established on July 27, 2001, and listed on November 1, 2022, specializes in the research, production, and sales of medical devices and consumables in the respiratory health field [1] - The company provides comprehensive treatment solutions for patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD), covering the entire cycle from diagnosis to chronic disease management [1] - The revenue composition of the company includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Fund Holdings - 华泰柏瑞基金旗下 has a significant holding in 瑞迈特, with 华泰柏瑞价值增长混合A (460005) holding 136,900 shares, representing 1.64% of the fund's net value, ranking as the tenth largest holding [2] - The fund has achieved a year-to-date return of 42.98% and a one-year return of 50.61%, indicating strong performance relative to its peers [2] Fund Manager Profile - The fund manager of 华泰柏瑞价值增长混合A is 方纬, who has been in the position for nearly 12 years, managing assets totaling 2.127 billion yuan [3] - During his tenure, the best fund return achieved was 260.51%, showcasing effective management skills [3]

Core Viewpoint - On October 10, 2023, Ruimait experienced a 2.91% increase in stock price with a trading volume of 123 million yuan, indicating positive market sentiment towards the company [1]. Financial Performance - For the first half of 2025, Ruimait achieved a revenue of 544 million yuan, representing a year-on-year growth of 42.30%. The net profit attributable to shareholders was 131 million yuan, also reflecting a growth of 42.19% [2]. - Cumulative cash dividends distributed by Ruimait since its A-share listing amount to 228 million yuan [3]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders in Ruimait decreased by 24.87% to 6,850, while the average circulating shares per person increased by 33.11% to 8,251 shares [2]. - On October 10, 2023, Ruimait's financing buy-in amounted to 12.20 million yuan, with a net buy of 3.00 million yuan, indicating strong investor interest [1]. - The total balance of margin trading for Ruimait reached 109 million yuan, accounting for 2.25% of its market capitalization, which is above the 50th percentile level over the past year [1]. Business Overview - Ruimait, established on July 27, 2001, specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2]. - The revenue composition of Ruimait includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders of Ruimait [3].

Core Viewpoint - The stock price of Ruimait has shown a significant increase of 35.98% year-to-date, despite recent declines in the short term, indicating volatility in the market [2]. Company Overview - Ruimait Medical Technology Co., Ltd. specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2]. - The company was established on July 27, 2001, and went public on November 1, 2022 [2]. - The revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2]. Financial Performance - For the first half of 2025, Ruimait reported a revenue of 544 million yuan, representing a year-on-year growth of 42.30%, and a net profit attributable to shareholders of 131 million yuan, also reflecting a growth of 42.19% [3]. - As of June 30, 2025, the number of shareholders decreased by 24.87% to 6,850, while the average circulating shares per person increased by 33.11% to 8,251 shares [3]. Market Activity - On September 24, Ruimait's stock price rose by 2.04% to 85.13 yuan per share, with a trading volume of 42.52 million yuan and a turnover rate of 0.89%, resulting in a total market capitalization of 7.628 billion yuan [1]. - The net outflow of main funds was 1.355 million yuan, with large orders accounting for 10.85% of purchases and 14.03% of sales [1]. Shareholder and Dividend Information - Since its A-share listing, Ruimait has distributed a total of 228 million yuan in dividends [4]. - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [4].

Group 1 - The core viewpoint of the news is that Ruimait has experienced a decline in stock price, with a cumulative drop of 6.36% over four consecutive days, currently trading at 85.52 yuan per share [1] - Ruimait Medical Technology Co., Ltd. specializes in the research, production, and sales of medical devices and consumables in the respiratory health field, primarily serving patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The company's main business revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Group 2 - According to data, Nord Fund holds a significant position in Ruimait, with its Nord Small and Mid-Cap Mixed Fund (570006) owning 18,000 shares, accounting for 5.02% of the fund's net value [2] - The fund has incurred a floating loss of approximately 10.46 million yuan during the four-day decline [2] - The Nord Small and Mid-Cap Mixed Fund has achieved a return of 45% year-to-date, ranking 1247 out of 8244 in its category [2]